Autologous chimeric antigen receptor (CAR)-modified T cells that target the B cell antigen CD19 and that express the CD137 (a costimulatory receptor) signalling domain have been used in adults with chronic lymphocytic leukaemia (CLL). Grupp et al. tested these cells in two children with relapsed and refractory pre-B cell acute lymphoblastic leukaemia (ALL). Although several adverse events occurred, both patients had a complete remission, and this is still ongoing in one patient after 11 months. The other patient relapsed after 2 months, with cells that no longer expressed CD19, indicating that other molecules may need to be targeted in some patients.
ORIGINAL RESEARCH PAPER
Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl. J. Med. 25 Mar 2013 (doi:10.1056/NEJMoa1215134)
Rights and permissions
About this article
Cite this article
Seton-Rogers, S. Modified CAR. Nat Rev Cancer 13, 295 (2013). https://doi.org/10.1038/nrc3525
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3525